Physician profile
John Steven Mathews
NPI 1326034562
$6,616.83
in general payments reported to CMS, 2019-2025
24 companies · $583 in 2025
The $583 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,156 · 2020: $602 · 2021: $949 · 2022: $1,150 · 2023: $1,164 · 2024: $1,013 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,098.25 | 2019-2025 | |
| Pfizer INC. | $571.32 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $515.21 | 2022-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $451.23 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.46 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $229.18 | 2023-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $223.70 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $154.87 | 2024-2025 | Voquezna |
| Mauna Kea Technologies, INC. | $154.65 | 2020-2021 | |
| Allergan, INC. | $148.96 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $132.58 | 2022-2023 | Dupixent |
| Aimmune Therapeutics, INC. | $120.24 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $106.86 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $93.89 | 2020-2024 | Linzess |
| Celgene Corporation | $49.02 | 2021-2023 | Zeposia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.92 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $46.53 | 2020-2021 | |
| Lilly USA, LLC | $40.49 | 2025 | Omvoh |
| Axonics, INC. | $40.32 | 2020-2021 | |
| Novo Nordisk INC | $33.65 | 2025 | Wegovy |
| Ardelyx, INC. | $23.19 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $21.88 | 2025 | Iqirvo |
| Organon LLC | $17.54 | 2023 | Hadlima |
| Redhill Biopharma INC. | $15.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.